Skip to NavigationSkip to content

Dr James Shannon joins Immodulon Therapeutics board of directors

Published on: 29/07/15

Dr James Shannon has joined Immodulon as a non-executive director with immediate effect.

Bringing with him 30 years’ of experience to Immodulon, having worked in senior positions in the pharma industry as chief medical officer at GlaxoSmithKline and global head of drug development for Novartis.

In Dr Shannon’s roles at GlaxoSmithKline and Novartis he was very involved in bringing highly innovative oncology products to the market. He has also served on the boards of a number of smaller biopharmaceutical companies.

He is also trained in medicine and cardiology, received undergraduate and graduate degrees at Queen's University Belfast and is a member of the Royal College of Physicians.

Dr Shannon says: "Immodulon has achieved a remarkable amount in a short period of time and generated some intriguing clinical data. I look forward to working with the team there as they guide IMM-101 through the next stages of its development towards the ultimate goal of making this potentially important therapy available for patients.

Immodulon Chairman, Charles Akle, comments: “James will bring a wealth of clinical development and regulatory experience and insight to the Immodulon board as we focus on our future development and progress towards Phase III of our lead product, IMM-101, in pancreatic cancer. We look forward to benefitting from his experience and counsel.” 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches